Coherus Oncology (CHRS) News
NASDAQ: CHRSHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.3698-0.0173 (-4.47%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CHRS news summary
We found 10 recent headlines mentioning Coherus Oncology (CHRS): 0 in the past week and 9 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, CHRS is down 4.47% at $0.3698. The most recent story, "Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Coherus Oncology headlines
- Weekly Buzz: LLY, JNJ Win FDA Nod; SION, NNOX, Cut Jobs; PFE, ARGX Strike Deals(RTTNews) - This week's biotech roundup features a series of regulatory approvals across obesity, stroke prevention, oncology, and medical devices, alongside workforce reductions and cost-cutting…NasdaqAMGN, ARGX, AZN, BEAM
- Oncolytics Partners With Coherus For Testing Pelareorep+LOQTORZI Combination In Anal Carcinoma(RTTNews) - Oncolytics Biotech Inc. (ONCY), a clinical-stage immunotherapy company, on Wednesday announced entering a clinical supply agreement with Coherus Oncology Inc. (CHRS) to evaluate the drug…NasdaqCHRS, ONCY, ET
- Coherus Oncology: 3 Key Takeaways for Long-Term InvestorsKey PointsCoherus Oncology is cutting headcount by 30% to reduce quarterly costs.Nasdaq
- Coherus Oncology (CHRS) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Coherus Oncology, Inc. Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization PlanCoherus Oncology, Inc. announced a strategic prioritization plan alongside its third quarter 2026 financial results. Under the plan, the company will focus its development efforts on…Nasdaq
- Coherus Oncology Reports Third Quarter 2026 Financial Results and Announces Strategic Prioritization Plan– Focus development efforts on tagmokitug/toripalimab as a potential best-in-disease treatment for esophageal cancer with plans for expedited development –GlobeNewswire
- Coherus Oncology, Inc. Reports 75% Confirmed ORR in First-Line ESCC Patients from Tagmokitug Interim Clinical DataOn October 28, 2026, Coherus Oncology, Inc. (the “Company”) issued a press release announcing the interim clinical data from the TREGCHECK™ development program evaluating…Nasdaq
- Coherus to Participate in Upcoming Investor ConferencesREDWOOD CITY, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS), today announced that the company will be webcasting its participation in the following upcoming investor…GlobeNewswire
- Coherus Oncology to Report Third Quarter 2026 Financial Results on November 9, 2026REDWOOD CITY, Calif., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS), today announced that its third quarter 2026 financial results will be released on Monday, November 9,…GlobeNewswire
- Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc . (Nasdaq: CHRS) today announced that the Company will release interim clinical data related to its tagmokitug…GlobeNewswire